Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
PFE Pfizer is mentioned as a key company in the sickle cell disease market, indicating its involvement in the sector but without specific positive or negative news. AGIO Agios Pharmaceuticals is listed as a key company in the sickle cell disease market, suggesting its participation in the field without specific sentiment. FULC Fulcrum Therapeutics is identified as a key company in the sickle cell disease market, indicating its presence without specific positive or negative commentary. NVO Novo Nordisk is mentioned as a key company in both the sickle cell disease and thalassemia markets, indicating its involvement in these therapeutic areas. SNY Sanofi is mentioned as a key company in the sickle cell disease, hemophilia A, and hemophilia B markets, indicating its broad presence in these therapeutic areas. ALNY Alnylam Pharmaceuticals is listed as a key company in the hemophilia and hemophilia A markets, indicating its involvement in these areas. BMRN BioMarin Pharmaceutical is listed as a key company in the hemophilia, hemophilia A, and thalassemia markets, indicating its involvement in these therapeutic areas. RGEN Regeneron Pharmaceuticals is mentioned as a key company in the thalassemia market, indicating its involvement in this therapeutic area. CRSP CRISPR Therapeutics is mentioned as a key company in the sickle cell disease market, indicating its involvement in gene therapy for the disease.

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight New York, USA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The sickle cell disease clinical trial analysis report delivers important insights into ongoing research of 50+ pipeline sickle cell disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Sickle Cell Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for sickle cell disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the sickle cell disease domain.

Sickle Cell Disease Clinical Trial Analysis Summary

Request a sample and discover the recent advances in sickle cell disease treatment @ https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

What is Sickle Cell Disease?

Sickle cell disease (SCD) is a group of inherited blood disorders caused by mutations in the HBB gene, which leads to the production of abnormal hemoglobin known as hemoglobin S. This causes red blood cells to become rigid and adopt a characteristic sickle or crescent shape, particularly under conditions of low oxygen. Unlike normal red blood cells, which are flexible and survive for about 120 days, sickled cells can break down prematurely, resulting in chronic hemolytic anemia, and may obstruct small blood vessels, causing painful vaso-occlusive crises and tissue damage. SCD can also lead to complications such as acute chest syndrome, stroke, infections, kidney dysfunction, and progressive organ damage. The disease is inherited in an autosomal recessive manner and includes several genotypes, with HbSS and HbSβ⁰-thalassemia generally associated with more severe disease.

Find out more about gene therapy for sickle cell disease @ Sickle Cell Disease New Treatment

A snapshot of the Pipeline Sickle Cell Disease Drugs mentioned in the report:

Learn more about the sickle cell disease research companies @ Sickle Cell Disease Clinical Trials

Stuti Mahajan, Functional Head of Consulting at DelveInsight, said that the sickle cell disease market is expected to shift toward more targeted and disease-modifying therapies, supported by the advancement of oral metabolic therapies, gene therapies, and fetal hemoglobin–inducing approaches. Positive Phase III data for etavopivat and the regulatory progress of mitapivat could expand pharmacological treatment options, while programs such as BEAM-101 and CS-206 may drive longer-term disease modification. Growing investment in novel mechanisms, including G9a inhibition, TMPRSS6 inhibition, hemopexin replacement, and anti-inflammatory approaches, is expected to further diversify the pipeline. Overall, the market outlook remains innovation-driven, with increasing emphasis on reducing VOCs, improving hemoglobin levels, and achieving durable treatment responses.

Recent Developments in Sickle Cell Disease Treatment Space

Scope of the Sickle Cell Disease Pipeline Report

Dive deep into rich insights for sickle cell disease cure, visit @ Sickle Cell Disease News

Table of Contents

For further information on the sickle cell disease clinical trials, reach out @ Sickle Cell Disease Medication

Related Reports

Sickle Cell Disease Market

Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCD companies, including Pfizer, Agios Pharmaceuticals, Fulcrum Therapeutics, Novo Nordisk, Scribe Therapeutics, Sanofi, and others.

Hemophilia Market

Hemophilia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia companies, including Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.

Hemophilia A Market

Hemophilia A Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia A companies, including Novo Nordisk, Ultragenyx Pharmaceutical, Sangamo Therapeutics, ASC Therapeutics, Roche, Chugai, Sanofi, Alnylam Pharmaceuticals, Pfizer, Genentech, BioMarin Pharmaceutical, HEMA Biologics, LFB Pharmaceuticals, Octapharma, CSL Behring, Octapharma, Bayer, Takeda, and others.

Hemophilia B Market

Hemophilia B Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia B companies, including UniQure Biopharma B.V., CSL Behring, Pfizer, Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

Thalassemia Market

Thalassemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thalassemia companies, including Novo Nordisk A/S, CorrectSequence Therapeutics Co., Ltd, Shanghai BDgene Co., Ltd., Bioray Laboratories, Mabwell (Shanghai) Bioscience Co., Ltd., Lantu Biopharma, Kind Pharmaceuticals LLC, Kanglin Biotechnology (Hangzhou) Co., Ltd., Pharmacosmos A/S, Regeneron Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.